Publications by authors named "Andreas Espehana"
Olfactory dysfunction affects approximately 20% of the population globally, with incidence increasing over the age of 60. The pathophysiology is complex, not yet fully understood, and depends on many factors, including the underlying cause. Despite this, the present literature on olfaction is limited due to significant heterogeneity in methodological approaches.
View Article and Find Full Text PDFPurpose Of Review: To provide a detailed overview of the assessment of COVID-19-related olfactory dysfunction and its association with psychological, neuropsychiatric, and cognitive symptoms.
Recent Findings: COVID-19-related olfactory dysfunction can have a detrimental impact to the quality of life of patients. Prior to the COVID-19 pandemic, olfactory and taste disorders were a common but under-rated, under-researched and under-treated sensory loss.
Systematic Review of Protein Biomarkers in Adult Patients With Chronic Rhinosinusitis.
Am J Rhinol Allergy
November 2023
Background: Chronic rhinosinusitis (CRS) is a heterogeneous condition characterized by differing inflammatory endotypes. The identification of suitable biomarkers could enable personalized approaches to treatment selection.
Objective: This study aimed to identify and summarize clinical studies of biomarkers in adults with CRS in order to inform future research into CRS endotypes.
Objectives: To determine the top 10 research priorities in Smell and Taste Disorders (SATD).
Design: After steering group was established, an electronic survey was disseminated to determine the list of questions. After removing out-of-scope responses, the remainder were consolidated to create summary questions.
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
Br J Haematol
September 2021
Article Synopsis
- Patients with chronic myeloid leukaemia (CML) receiving targeted cancer treatments, like tyrosine kinase inhibitors (TKIs), are considered highly vulnerable to SARS-CoV-2 and may not respond adequately to a single dose of the Pfizer-BioNTech COVID-19 vaccine.
- A study evaluated immune responses in 16 CML patients after their first BNT162b2 vaccine dose, finding that 87.5% developed anti-Spike immunoglobulin G and all patients generated a neutralizing antibody response.
- Additionally, 93.3% of evaluable patients showed T-cell responses, with 80% displaying polyfunctional responses, indicating that a single vaccine dose is immunogenic for most CML patients
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.
Leukemia
December 2021